Compare Janus Living Inc. Class A-1 Common Stock (JAN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Janus Living Inc. Class A-1 Common Stock vs TransMedics Group Inc — how do they compare? Janus Living Inc. Class A-1 Common Stock trades at $28.51 (market cap $6.79B), while TransMedics Group Inc trades at $75.5 (market cap $2.62B). The key difference: Janus Living Inc. Class A-1 Common Stock is far larger — about 2.6× TransMedics Group Inc's market cap, and Janus Living Inc. Class A-1 Common Stock pays a 1.97% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Janus Living Inc. Class A-1 Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| JAN | TMDX | |
|---|---|---|
Market Cap | $6.79B | $2.62B |
Volume | 1,802,875 | 891,435 |
Sector | Real Estate | Health |
52-Week High | $31.76 | $150.42 |
52-Week Low | $22.88 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $6.88B | $3.01B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JAN trades at $28.85, up 0.42% today, with a neutral technical signal. The company, a senior housing REIT, reported a net loss of $61.10M in 2025, though revenue grew to $771.17M. Analyst sentiment is strongly positive with a 100% buy rating and a $32.91 consensus price target, representing a 14% upside. Recent developments include closing a $1.25 billion credit facility and declaring quarterly dividends.
The outlook is cautiously optimistic, driven by strong analyst support and strategic growth initiatives. Key opportunities include accretive acquisitions funded by recent capital raises. Risks include persistent negative profit margins, execution challenges in integrating new assets, and sensitivity to interest rate changes affecting REIT valuations.
TransMedics Group (TMDX) trades at $79.135, up 1.23% on the day, but faces a bearish technical signal with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 58.69% gross margin and 22.69% net margin, though net income is projected to decline in 2026. Recent news highlights insider buying and CFO appointment, but also ongoing legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but risks include margin pressure from heavy investment and legal overhangs. Upside hinges on execution against guidance, while downside is cushioned by solid cash flow and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Janus Living Inc. Class A-1 Common Stock
Janus Living, Inc. is a real estate investment trust that owns and operates senior housing communities in US. Its portfolio comprises roughly 34 communities across 10 states, structured under RIDEA arrangements and externally managed by Healthpeak Investment Management.
Read more on JAN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
